Yu Chien Fredriksson

Title: Yu Chien Fredriksson: Innovator in Fixed Dose Combinations

Introduction

Yu Chien Fredriksson is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of fixed dose combinations for cancer treatment. His innovative work has led to advancements in patient care and treatment efficacy.

Latest Patents

Fredriksson holds a patent for a fixed dose combination of pertuzumab and trastuzumab, which is administered subcutaneously to patients. This invention, titled "Pertuzumab plus trastuzumab fixed dose combination," also includes the optional use of recombinant human hyaluronidase (rHuPH20). The patent encompasses the final efficacy and safety data from the FeDeriCa clinical trial, as well as the United States Prescribing Information (USPI) and primary analysis of the PHranceSCa clinical trial. He has 1 patent to his name.

Career Highlights

Throughout his career, Fredriksson has worked with prominent companies in the pharmaceutical industry. He has been associated with Genentech, Inc. and Hoffmann-La Roche Inc., where he has contributed to groundbreaking research and development projects. His expertise in drug formulation and clinical trials has been instrumental in advancing cancer therapies.

Collaborations

Fredriksson has collaborated with several professionals in his field, including Tanja Badovinac-Crnjevic and Sarah Heeson. These collaborations have fostered innovation and have been crucial in the successful development of his patented inventions.

Conclusion

Yu Chien Fredriksson is a distinguished inventor whose work in fixed dose combinations has made a significant impact on cancer treatment. His contributions to the pharmaceutical industry continue to influence patient care and therapeutic strategies.